Close Menu

NEW YORK (360Dx) – Specific Diagnostics announced today that CARB-X has awarded $1.7 million in second-stage funding for development of its Reveal rapid antibiotic susceptibility test (AST) instrument, based on the firm achieving development and testing milestones.

Mountain View, California-based Specific Diagnostics said that the additional funding will enable its preparation for clinical trials this year. It is readying the system for regulatory validation to enable its launch and use in hospitals.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.